Cargando…

Faecal Metabolomics in Paediatric Inflammatory Bowel Disease: A Systematic Review

BACKGROUND AND AIMS: Paediatric inflammatory bowel disease [IBD] is characterized by altered immunological and metabolic pathways. Metabolomics may therefore increase pathophysiological understanding and could develop into characterization of biomarkers for diagnosis and IBD treatment response. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Jagt, Jasmijn Z, Verburgt, Charlotte M, de Vries, Ralph, de Boer, Nanne K H, Benninga, Marc A, de Jonge, Wouter J, van Limbergen, Johan E, de Meij, Tim G J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683079/
https://www.ncbi.nlm.nih.gov/pubmed/35679608
http://dx.doi.org/10.1093/ecco-jcc/jjac079
_version_ 1784834994483494912
author Jagt, Jasmijn Z
Verburgt, Charlotte M
de Vries, Ralph
de Boer, Nanne K H
Benninga, Marc A
de Jonge, Wouter J
van Limbergen, Johan E
de Meij, Tim G J
author_facet Jagt, Jasmijn Z
Verburgt, Charlotte M
de Vries, Ralph
de Boer, Nanne K H
Benninga, Marc A
de Jonge, Wouter J
van Limbergen, Johan E
de Meij, Tim G J
author_sort Jagt, Jasmijn Z
collection PubMed
description BACKGROUND AND AIMS: Paediatric inflammatory bowel disease [IBD] is characterized by altered immunological and metabolic pathways. Metabolomics may therefore increase pathophysiological understanding and could develop into characterization of biomarkers for diagnosis and IBD treatment response. However, no uniform metabolomic profiles have been identified to date. This systematic review aimed to identify faecal metabolomic signatures in paediatric IBD vs controls, and to describe metabolites associated with disease activity and treatment response. METHODS: A literature search was performed in Embase, Medline, Web of Science and Cochrane Library. Studies assessing faecal metabolomics in paediatric patients < 18 years with IBD [de novo, active, inactive] with comparative groups [IBD vs non-IBD; responders vs non-responders] were included. The quality of included studies was assessed according to the Newcastle–Ottawa Scale. RESULTS: Nineteen studies were included [540 patients with IBD, 386 controls], assessing faecal short-chain fatty acids [SCFA] [five studies], amino acids [AA] [ten studies], bile acids [BA] [eight studies] and other metabolites [nine studies] using various methodologies. Significantly increased levels of AA [particularly phenylalanine], primary BA and lower levels of secondary BA were described in paediatric IBD compared to controls. Faecal SCFA results varied across studies. Additionally, responders and non-responders to exclusive enteral nutrition and infliximab showed differences in baseline faecal metabolites [based on BA, AA]. CONCLUSIONS: This systematic review provides evidence for distinct faecal metabolomic profiles in paediatric IBD. However, results varied across studies, possibly due to differences in study design and applied analytical techniques. Faecal metabolomics could provide more insight into host–microbial interactions in IBD, but further studies with standardized methodologies and reporting are needed.
format Online
Article
Text
id pubmed-9683079
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96830792022-11-25 Faecal Metabolomics in Paediatric Inflammatory Bowel Disease: A Systematic Review Jagt, Jasmijn Z Verburgt, Charlotte M de Vries, Ralph de Boer, Nanne K H Benninga, Marc A de Jonge, Wouter J van Limbergen, Johan E de Meij, Tim G J J Crohns Colitis Review Article BACKGROUND AND AIMS: Paediatric inflammatory bowel disease [IBD] is characterized by altered immunological and metabolic pathways. Metabolomics may therefore increase pathophysiological understanding and could develop into characterization of biomarkers for diagnosis and IBD treatment response. However, no uniform metabolomic profiles have been identified to date. This systematic review aimed to identify faecal metabolomic signatures in paediatric IBD vs controls, and to describe metabolites associated with disease activity and treatment response. METHODS: A literature search was performed in Embase, Medline, Web of Science and Cochrane Library. Studies assessing faecal metabolomics in paediatric patients < 18 years with IBD [de novo, active, inactive] with comparative groups [IBD vs non-IBD; responders vs non-responders] were included. The quality of included studies was assessed according to the Newcastle–Ottawa Scale. RESULTS: Nineteen studies were included [540 patients with IBD, 386 controls], assessing faecal short-chain fatty acids [SCFA] [five studies], amino acids [AA] [ten studies], bile acids [BA] [eight studies] and other metabolites [nine studies] using various methodologies. Significantly increased levels of AA [particularly phenylalanine], primary BA and lower levels of secondary BA were described in paediatric IBD compared to controls. Faecal SCFA results varied across studies. Additionally, responders and non-responders to exclusive enteral nutrition and infliximab showed differences in baseline faecal metabolites [based on BA, AA]. CONCLUSIONS: This systematic review provides evidence for distinct faecal metabolomic profiles in paediatric IBD. However, results varied across studies, possibly due to differences in study design and applied analytical techniques. Faecal metabolomics could provide more insight into host–microbial interactions in IBD, but further studies with standardized methodologies and reporting are needed. Oxford University Press 2022-06-09 /pmc/articles/PMC9683079/ /pubmed/35679608 http://dx.doi.org/10.1093/ecco-jcc/jjac079 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Review Article
Jagt, Jasmijn Z
Verburgt, Charlotte M
de Vries, Ralph
de Boer, Nanne K H
Benninga, Marc A
de Jonge, Wouter J
van Limbergen, Johan E
de Meij, Tim G J
Faecal Metabolomics in Paediatric Inflammatory Bowel Disease: A Systematic Review
title Faecal Metabolomics in Paediatric Inflammatory Bowel Disease: A Systematic Review
title_full Faecal Metabolomics in Paediatric Inflammatory Bowel Disease: A Systematic Review
title_fullStr Faecal Metabolomics in Paediatric Inflammatory Bowel Disease: A Systematic Review
title_full_unstemmed Faecal Metabolomics in Paediatric Inflammatory Bowel Disease: A Systematic Review
title_short Faecal Metabolomics in Paediatric Inflammatory Bowel Disease: A Systematic Review
title_sort faecal metabolomics in paediatric inflammatory bowel disease: a systematic review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683079/
https://www.ncbi.nlm.nih.gov/pubmed/35679608
http://dx.doi.org/10.1093/ecco-jcc/jjac079
work_keys_str_mv AT jagtjasmijnz faecalmetabolomicsinpaediatricinflammatoryboweldiseaseasystematicreview
AT verburgtcharlottem faecalmetabolomicsinpaediatricinflammatoryboweldiseaseasystematicreview
AT devriesralph faecalmetabolomicsinpaediatricinflammatoryboweldiseaseasystematicreview
AT deboernannekh faecalmetabolomicsinpaediatricinflammatoryboweldiseaseasystematicreview
AT benningamarca faecalmetabolomicsinpaediatricinflammatoryboweldiseaseasystematicreview
AT dejongewouterj faecalmetabolomicsinpaediatricinflammatoryboweldiseaseasystematicreview
AT vanlimbergenjohane faecalmetabolomicsinpaediatricinflammatoryboweldiseaseasystematicreview
AT demeijtimgj faecalmetabolomicsinpaediatricinflammatoryboweldiseaseasystematicreview